Big tumor regression induced by GM-CSF gene-modified 3LL tumor cells via facilitating DC maturation and deviation toward CD11c+CD8α + subset

DNA and Cell Biology

Volumn 26, Issue 12, 2007, Pages 863-872

  Lin, Yi ^a   Xiong, Sidong ^a,b   Zhang, Lei ^a   Zhang, Yi ^a   Cai, Yuchan ^a   Xu, Lin ^a   Chu, Yiwei ^a,b  

^a FUDAN UNIVERSITY   (China)

^b University of Shanghai   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD8ALPHA ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOMA; CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DNA MODIFICATION; DRUG EFFICACY; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; INOCULATION; LEWIS CARCINOMA; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; TUMOR MODEL; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD11C; ANTIGENS, CD8; BASE SEQUENCE; CARCINOMA, LEWIS LUNG; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DNA PRIMERS; FEMALE; GENE THERAPY; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL;

MURINAE; MUS;

EID: 37249006729     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2007.0632     Document Type: Article

References (36)

1. Bartz, H., Avalos, N.M., Baetz, A., Heeg, K., and Dalpke, A.H. (2006). Involvement of suppressors of cytokine signaling in toll-like receptor-mediated block of dendritic cell differentiation. Blood 108, 4102-4108.
2. Belardelli, F., and Ferrantini, M. (2002). Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23, 201-208.
3. Belz, G.T., Shortman, K., Bevan, M.J., and Heath, W.R. (2005). CD8alpha+ dendritic cells selectively present MHC class I-restricted noncytolytic viral and intracellular bacterial antigens in vivo. J Immunol 175, 196-200.
4. Berns, A.J., Clift, S., Cohen, L.K., Donehower, R.C., Dranoff, G., Hauda, K.M., Jaffee, E.M., Lazenby, A.J., Levitsky, H.I., and Marshall, F.F. (1995). Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther 6, 347-368.
5. Chang, C.J., Chen, Y.H., Huang, K.W., Cheng, H.W., Chan, S.F., Tai, K.F., and Hwang, L.H. (2007). Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology 45, 746-754.
6. Chu, Y., Wang, L.X., Yang, G., Ross, H.J., Urba, W.J., Prell, R., Jooss, K., Xiong, S., and Hu, H.M. (2006). Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother 29, 367-380.
7. De Giovanni, C., Nicoletti, G., Landuzzi, L., Astolfi, A., Croci, S., Comes, A., Ferrini, S., Meazza, R., Iezzi, M., Di Carlo, E., Musiani, P., Cavallo, F., Nanni, P., and Lollini, P.L. (2004). Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res 64, 4001-4009.
8. den Haan, J.M., Lehar, S.M., and Bevan, M.J. (2000). CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 192, 1685-1696.
9. Dranoff, G. (2002). GM-CSF-based cancer vaccines. Immunol Rev 188, 147-154.
10. Dranoff, G. (2003). GM-CSF-secreting melanoma vaccines. Oncogene 22, 3188-3192.
11. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90, 3539-3543.
12. Ellem, K.A., O'rourke, M.G., Johnson, G.R., Parry, G., Misko, I.S., Schmidt, C.W., Parsons, P.G., Burrows, S.R., Cross, S., Fell, A., Li, C.L., Bell, J.R., Dubois, P.J., Moss, D.J., Good, M.F., Kelso, A., Cohen, L.K., Dranoff, G., and Mulligan, R.C. (1997). A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony- stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 44, 10-20.
13. Fuchs, R.P., and Napolitano, R.L. (1998). Inactivation of DNA proofreading obviates the need for SOS induction in frame-shift mutagenesis. Proc Natl Acad Sci USA 95, 13114-13119.
14. Gao, J.Q., Kanagawa, N., Motomura, Y., Yanagawa, T., Sugita, T., Hatanaka, Y., Tani, Y., Mizuguchi, H., Tsutsumi, Y., Mayumi, T., Okada, N., and Nakagawa, S. (2007). Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer. Gene Ther 14, 491-502.
15. Jaffee, E.M., Hruban, R.H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P.R., Goemann, M., Coleman, J., Grochow, L., Donehower, R.C., Lillemoe, K.D., O'reilly, S., Abrams, R.A., Pardoll, D.M., Cameron, J.L., and Yeo, C.J. (2001). Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19, 145-156.
16. Kamath, A.T., Henri, S., Battye, F., Tough, D.F., and Shortman, K. (2002). Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 100, 1734-1741.
17. Larsen, C.P., Ritchie, S.C., Hendrix, R., Linsley, P.S., Hathcock, K.S., Hodes, R.J., Lowry, R.P., and Pearson, T.C. (1994). Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 152, 5208-5219.
18. Lee, Y.S., Han, O.K., Park, C.W., Suh, S.I., Shin, S.W., Yang, C.H., Jeon, T.W., Lee, E.S., Kim, K.J., Kim, S.H., Yoo, W.K., and Kim, H.J. (2003). Immunomodulatory effects of aqueousextracted astragali radix in methotrexate-treated mouse spleen cells. J Ethnopharmacol 84, 193-198.
19. Liao, H.X., Cianciolo, G.J., Staats, H.F., Scearce, R.M., Lapple, D.M., Stauffer, S.H., Thomasch, J.R., Pizzo, S.V., Montefiori, D.C., Hagen, M., Eldridge, J., and Haynes, B.F. (2002). Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF. Vaccine 20, 2396-2403.
20. Maldonado-Lopez, R., Maliszewski, C., Urbain, J., and Moser, M. (2001). Cytokines regulate the capacity of CD8alpha(+) and CD8alpha(-) dendritic cells to prime Th1/Th2 cells in vivo. J Immunol 167, 4345-4350.
21. Nakazaki, Y., Hase, H., Inoue, H., Beppu, Y., Meng, X.K., Sakaguchi, G., Kurita, R., Asano, S., Nakamura, Y., and Tani, K. (2006). Serial analysis of gene expression in progressing and regressing mouse tumors implicates the involvement of RANTES and TARC in antitumor immune responses. Mol Ther 14, 599-606.
22. Nemunaitis, J., and Murray, N. (2006). Immune-modulating vaccines in non-small cell lung cancer. J Thorac Oncol 1, 756-761.
23. Nguyen, L.T., Elford, A.R., Murakami, K., Garza, K.M., Schoenberger, S.P., Odermatt, B., Speiser, D.E., and Ohashi, P.S. (2002). Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med 195, 423-435.
24. Overwijk, W.W., Theoret, M.R., Finkelstein, S.E., Surman, D.R., De Jong, L.A., Vyth-Dreese, F.A., Dellemijn, T.A., Antony, P.A., Spiess, P.J., Palmer, D.C., Heimann, D.M., Klebanoff, C.A., Yu, Z., Hwang, L.N., Feigenbaum, L., Kruisbeek, A.M., Rosenberg, S.A., and Restifo, N.P. (2003). Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198, 569-580.
25. Pooley, J.L., Heath, W.R., and Shortman, K. (2001). Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8-dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol 166, 5327-5330.
26. Portielje, J.E., Gratama, J.W., Van Ojik, H.H., Stoter, G., and Kruit, W.H. (2002). IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 52, 133-144.
27. Rossner, S., Voigtlander, C., Wiethe, C., Hanig, J., Seifarth, C., and Lutz, M.B. (2005). Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol 35, 3533-3544.
28. Salgia, R., Lynch, T., Skarin, A., Lucca, J., Lynch, C., Jung, K., Hodi, F.S., Jaklitsch, M., Mentzer, S., Swanson, S., Lukanich, J., Bueno, R., Wain, J., Mathisen, D., Wright, C., Fidias, P., Donahue, D., Clift, S., Hardy, S., Neuberg, D., Mulligan, R., Webb, I., Sugarbaker, D., Mihm, M., and Dranoff, G. (2003). Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21, 624-630.
29. Simons, J.W., Jaffee, E.M., Weber, C.E., Levitsky, H.I., Nelson, W.G., Carducci, M.A., Lazenby, A.J., Cohen, L.K., Finn, C.C., Clift, S.M., Hauda, K.M., Beck, L.A., Leiferman, K.M., Owens, A.H., Jr., Piantadosi, S., Dranoff, G., Mulligan, R.C., Pardoll, D.M., and Marshall, F.F. (1997). Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57, 1537-1546.
30. Simons, J.W., Mikhak, B., Chang, J.F., Demarzo, A.M., Carducci, M.A., Lim, M., Weber, C.E., Baccala, A.A., Goemann, M.A., Clift, S.M., Ando, D.G., Levitsky, H.I., Cohen, L.K., Sanda, M.G., Mulligan, R.C., Partin, A.W., Carter, H.B., Piantadosi, S., Marshall, F.F., and Nelson, W.G. (1999). Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59, 5160-5168.
31. Tartour, E., Mathiot, C., and Fridman, W.H. (1992). Current status of interleukin-2 therapy in cancer. Biomed. Pharmacother. 46, 473-484.
32. Vremec, D., Pooley, J., Hochrein, H., Wu, L., and Shortman, K. (2000). CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol 164, 2978-2986.
33. Wysocki, P.J., Zolnierek, J., Szczylik, C., and Mackiewicz, A. (2007). Recent developments in renal cell cancer immunotherapy. Expert Opin Biol Ther 7, 727-737.
34. Yu, P., Lee, Y., Liu, W., Chin, R.K., Wang, J., Wang, Y., Schietinger, A., Philip, M., Schreiber, H., and Fu, Y.X. (2004). Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5, 141-149.
35. Zhang, X., Divangahi, M., Ngai, P., Santosuosso, M., Millar, J., Zganiacz, A., Wang, J., Bramson, J., and Xing, Z. (2007). Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine 25, 1342-1352.
36. Zhou, X., Jun, D.Y., Thomas, A.M., Huang, X., Huang, L.Q., Mautner, J., Mo, W., Robbins, P.F., Pardoll, D.M., and Jaffee, E.M. (2005). Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocytemacrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Res 65, 1079-1088.